Lee H Chen
Overview
Explore the profile of Lee H Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
557
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kwok D, Stevers N, Etxeberria I, Nejo T, Colton Cove M, Chen L, et al.
Nature
. 2025 Feb;
639(8054):463-473.
PMID: 39972144
T cell-based immunotherapies hold promise in treating cancer by leveraging the immune system's recognition of cancer-specific antigens. However, their efficacy is limited in tumours with few somatic mutations and substantial...
2.
Nejo T, Wang L, Leung K, Wang A, Lakshmanachetty S, Gallus M, et al.
Sci Rep
. 2024 Mar;
14(1):6362.
PMID: 38493204
Despite advancements in cancer immunotherapy, solid tumors remain formidable challenges. In glioma, profound inter- and intra-tumoral heterogeneity of antigen landscape hampers therapeutic development. Therefore, it is critical to consider alternative...
3.
Nejo T, Wang L, Leung K, Wang A, Lakshmanachetty S, Gallus M, et al.
bioRxiv
. 2023 Nov;
PMID: 37961484
Background: Despite advancements in cancer immunotherapy, solid tumors remain formidable challenges. In glioma, profound inter-and intra-tumoral heterogeneity of antigen landscape hampers therapeutic development. Therefore, it is critical to consider alternative...
4.
Kwok D, Stevers N, Nejo T, Chen L, Etxeberria I, Jung J, et al.
bioRxiv
. 2023 Oct;
PMID: 37904942
T-cell-mediated immunotherapies are limited by the extent to which cancer-specific antigens are homogenously expressed throughout a tumor. We reasoned that recurrent splicing aberrations in cancer represent a potential source of...
5.
Sun M, Yang R, Liu H, Wang W, Song X, Hu B, et al.
Cancers (Basel)
. 2023 Sep;
15(18).
PMID: 37760589
Brain tumor-initiating cells (BTICs) and tumor cell plasticity promote glioblastoma (GBM) progression. Here, we demonstrate that clemastine, an over-the-counter drug for treating hay fever and allergy symptoms, effectively attenuated the...
6.
Singh S, Yang R, Roso K, Hansen L, Du C, Chen L, et al.
Biomedicines
. 2022 Apr;
10(4).
PMID: 35453502
Glioblastoma (GBM) is a lethal brain cancer exhibiting high levels of drug resistance, a feature partially imparted by tumor cell stemness. Recent work shows that homozygous deletion, a genetic alteration...
7.
Xu C, Liu H, Pirozzi C, Chen L, Greer P, Diplas B, et al.
Acta Neuropathol Commun
. 2021 Nov;
9(1):178.
PMID: 34732238
Diffuse intrinsic pontine gliomas (DIPGs) are high-grade tumors of the brainstem that often occur in children, with a median overall survival of less than one year. Given the fact that...
8.
Chen L, Pan C, Diplas B, Xu C, Hansen L, Wu Y, et al.
Nat Commun
. 2020 Jun;
11(1):3077.
PMID: 32555164
Brainstem gliomas are a heterogeneous group of tumors that encompass both benign tumors cured with surgical resection and highly lethal cancers with no efficacious therapies. We perform a comprehensive study...
9.
Wang Z, Xu C, Diplas B, Moure C, Chen C, Chen L, et al.
Mol Cancer Res
. 2020 Apr;
18(7):968-980.
PMID: 32229503
Diffuse intrinsic pontine glioma (DIPG) is an invariably fatal brain tumor occurring predominantly in children. Up to 90% of pediatric DIPGs harbor a somatic heterozygous mutation resulting in the replacement...
10.
Moure C, Diplas B, Chen L, Yang R, Pirozzi C, Wang Z, et al.
Mol Cancer Res
. 2019 Jul;
17(10):2042-2050.
PMID: 31292202
Mutations in isocitrate dehydrogenases 1 and 2 (IDH) occur in the majority of World Health Organization grade II and III gliomas. IDH1/2 active site mutations confer a neomorphic enzyme activity...